BAY1067197
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- BAY1067197
- Molecular weight
- 716.29
- Structure (SMILES)
- C[C@H](N)C(=O)N[C@@H](C)C(=O)OCCOc1ccc(-c2c(C#N)c(SCc3csc(-c4ccc(Cl)cc4)n3)nc(N3CCCC3)c2C#N)cc1
- bay 10 67197
- bay 1067197
- bay 1067197 hcl 10 mg tablet
- BAY-10-67197
- BAY-1067197
- bay10 67197
- BAY10-67197
- bay1067197
- Bay1067197
- BAY1067197
- BAY1067197 (10 mg)
- BAY1067197 (treatment 2)
- bialanate de neladenoson
- Bialanate de neladenoson
- bialanato de neladenoson
- Bialanato de neladenoson
- neladenoson bialanate
- Neladenoson bialanate
- Neladenoson bialanate (BAY 1067197)
- Neladenoson bialanate (BAY1067197)
- neladenoson bialanate [INN]
- Neladenoson bialanate [WHO-DD]
- neladenoson bialanate inn
- neladenoson bialanate who dd
- neladenoson dalanate
And 1 more, listed on the interactive page.
- CAS registry numbers
- 1239309-58-0
- ChEMBL ID
- CHEMBL5314392
- InChIKey
- WESNEIGKOAXSGX-VXKWHMMOSA-N
- PubChem compound IDs
- 56848985
- FDA ingredient codes (UNII)
- IV690462VZ
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- neladenoson
- Type
- Synthetic organic
- Mechanism
- Adenosine A1 receptor agonist
- Action type
- Agonist
- Target
- Adenosine receptor A1
- Protein identifier
- P30542
- Action type
- PARTIAL_AGONIST
- Target
- A<sub>1</sub> receptor
- Gene symbol
- A<sub>1</sub> receptor
Open Targets mechanisms
- Mechanism
- Adenosine A1 receptor agonist
- Action type
- Agonist
- Target
- Adenosine receptor A1
Investigated indications
- Condition
- Heart Failure
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 2
- NCT01945606
- NCT02040233
- NCT02992288
- NCT03098979
- Hydrogen bond acceptors
- 12
- Hydrogen bond donors
- 2
- Polar surface area
- 167.25
- Calculated partition coefficient (ALogP)
- 5.94
- Calculated partition coefficient (XLogP)
- 5.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 3
- Rotatable bonds
- 13
- Heavy atoms
- 49
- Molecular formula
- C35H34ClN7O4S2
- Monoisotopic mass
- 715.1802226
- Natural product
- Yes
Related records
Trials (16)
- A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- A Study to Compare the Efficacy of Alendronate With and Without Calcium or Calcium Alone In the Treatment of Osteoporosis in Postmenopausal Women (0217-088)(COMPLETED)
- A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
- A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction
- Drug-Drug Interaction of Clomipramine HCl and Sildenafil Citrate in Healthy Males
- MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
- Multiple Dose Study in Heart Failure of BAY 1067197
- Ondansetron Versus Metoclopramide in Treatment of Vomiting in Gastroenteritis
- Phase III Cat-PAD Follow-on Study
- Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers
- Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
- Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose in Participants With Liver Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
- Study on the Safety of Neladenoson Bialanate, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Dug Given as a Single Oral Dose of 10 mg Immediate Release Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight
- Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker
- Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers
- Study to Evaluate Pharmacokinetic and Bioavailability of Envarsus® vs. Advagraf® in Liver Transplant Recipients
In development for (1)
- Heart failure Phase 2
Targets (1)
- ADORA1 Adenosine A1 receptor agonist